Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion type Assertion NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_head.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion description "[Furthermore, CD24 may contribute to resistance to HER2-targeted therapy and, therefore, is itself a potential therapeutic target in HER2-positive breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_provenance.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion evidence source_evidence_literature NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_provenance.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion SIO_000772 24754246 NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_provenance.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion wasDerivedFrom befree-2016 NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_provenance.
- NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_assertion wasGeneratedBy ECO_0000203 NP1175619.RA-2p24gT8kGwxpX95F97VZPQjf4DOL8DeBegP37OQmHw130_provenance.